Curasight A/S

Curasight A/S has a liquidity risk profile marked by a current ratio of 1.37 and a debt-to-equity ratio of 1.4, indicating moderate leverage and a need for close monitoring of cash flow. The company reported negative operating and free cash flows of -51.7 million DKK and -52.4 million DKK, respectively, in the latest period. The negative net cash position, after subtracting total debt, further underscores the liquidity risk. Profitability metrics are weak, with a return on equity of -296.78% and a return on assets of -106.34%, both significantly below the industry median for biotechnology and medical research firms. These figures suggest the company is not generating returns for shareholders or effectively utilizing its assets. The company operates as a single-segment entity, with all revenue derived from its PET imaging platform. There is no geographic diversification disclosed, and the company is entirely based in Denmark. This lack of geographic and segment diversification increases exposure to regional economic and regulatory risks. Growth trajectory is negative, with the company reporting a revenue of -49.68 million DKK in the latest period. Analysts expect continued losses, with a mean EBIT estimate of -64 million DKK for the current fiscal year. The company has not demonstrated a path to positive revenue or profitability in the near term. Risk factors include a high liquidity risk due to negative operating and free cash flows, and a debt-to-equity ratio of 1.4. The risk assessment also flags a negative net cash position after subtracting total debt. There is no indication of dilution pressure in the near term, with dilution risk rated as low. Recent events include the continued development of the PET imaging platform targeting uPAR, with no major regulatory or financial events disclosed in the latest filings. The company remains in a pre-revenue phase, with all financials reflecting ongoing R&D and operational costs.